Cargando…

Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA

Aims: Determining the origin of metastases is an important task of pathologists to allow for the initiation of a tumor-specific therapy. Recently, homeobox protein Hox-B13 (HOXB13) has been suggested as a new marker for the detection of prostatic origin. The aim of this study was to evaluate the dia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kristiansen, Ilka, Stephan, Carsten, Jung, Klaus, Dietel, Manfred, Rieger, Anja, Tolkach, Yuri, Kristiansen, Glen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485975/ https://www.ncbi.nlm.nih.gov/pubmed/28555048 http://dx.doi.org/10.3390/ijms18061151

Ejemplares similares

Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
por: Yin, Ming, et al.
Publicado: (2007)

Identification of an HLA-A(*)0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein
por: Kiessling, A, et al.
Publicado: (2004)

Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers
por: Kremer, Anika, et al.
Publicado: (2019)

Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer
por: Stinnesbeck, Melissa, et al.
Publicado: (2021)

ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer
por: ADLER, DAVID, et al.
Publicado: (2012)

ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
por: Hernández-Llodrà, Silvia, et al.
Publicado: (2017)

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy
por: Zabalza, Cristina Villares, et al.
Publicado: (2015)

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer
por: Schaefer, G, et al.
Publicado: (2013)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

A Comparison of the Biological Features of Prostate Cancer with (PSA+, PSMA+) Profile according to RKIP
por: Ben Jemaa, Awatef, et al.
Publicado: (2013)

Diagnostic Efficacy of PSMA and PSCA mRNAs Combined to PSA in Prostate Cancer Patients
por: Mahmoud, Mustafa M, et al.
Publicado: (2023)

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer
por: Heumann, Asmus, et al.
Publicado: (2018)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

HOXB5 Cooperates with NKX2-1 in the Transcription of Human RET
por: Zhu, Jiang, et al.
Publicado: (2011)

Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
por: Bhalla, Ritu, et al.
Publicado: (2013)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers
por: Burdelski, Christoph, et al.
Publicado: (2015)

Immunohistochemical Expression of Alpha-Methyl-Coa (AMACR) and ERG in Prostatic Adenocarcinoma and Prostatic Hyperplasia: A Comparative Study
por: Samir Sayed, Rasha Mohamed, et al.
Publicado: (2023)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence
por: Bianchi, Lorenzo, et al.
Publicado: (2022)

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
por: Weichert, W, et al.
Publicado: (2008)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells
por: Bauer, Simone, et al.
Publicado: (2021)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer
por: Meller, Sebastian, et al.
Publicado: (2015)

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
por: Falkenbach, Fabian, et al.
Publicado: (2023)

Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging
por: Tolkach, Yuri, et al.
Publicado: (2019)

Androgen Receptor Splice Variants Contribute to the Upregulation of DNA Repair in Prostate Cancer
por: Tolkach, Yuri, et al.
Publicado: (2022)

Genetic Interaction between Tmprss2-ERG Gene Fusion and Nkx3.1-Loss Does Not Enhance Prostate Tumorigenesis in Mouse Models
por: Linn, Douglas E., et al.
Publicado: (2015)

Prostate cancer risk variants of the HOXB genetic locus
por: Dupont, William D., et al.
Publicado: (2021)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Identification of F-Box/SPRY Domain-Containing Protein 1 (FBXO45) as a Prognostic Biomarker for TMPRSS2–ERG-Positive Primary Prostate Cancers
por: von Danwitz, Marthe, et al.
Publicado: (2023)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer
por: Weber, Achim, et al.
Publicado: (2008)

ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation
por: Lorenzoni, Marco, et al.
Publicado: (2022)

Determination of ERG(+), EZH2, NKX3.1, and SPINK‐1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer
por: Segura‐Moreno, Yenifer Yamile, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9522dd942agp53e0so86ijo33g